Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Administration de liquides dans l'acidocétose (BOIRE) (DRINK)

5 novembre 2026 mis à jour par: Centre Hospitalier Universitaire de Nice

Comparaison de la solution saline et du Ringer Lactate chez les patients atteints d'acidocétose diabétique sévère (DRINK) : un essai contrôlé randomisé en double aveugle

Management of severe diabetic ketoacidosis is based on insulin therapy, correction of metabolic disorders and fluid resuscitation. Current recommendations recommend the first-line use of isotonic saline, whose composition is unbalanced, rich in chloride and sodium compared with plasma. Administration of large volumes of isotonic saline is associated with a risk of hyperchloremic metabolic acidosis and acute renal failure. Balanced solutions (e.g. Ringer Lactate) are solutions with a more balanced electrolyte composition close to that of plasma. They could therefore enable diabetic ketoacidosis to be resolved more quickly than isotonic saline, due to a lower risk of hyperchloremic acidosis. Preliminary data suggest a potential benefit of balanced solutions for fluid resuscitation of patients with severe diabetic ketoacidosis in terms of resolution of diabetic ketoacidosis, but no randomized controlled double-blind study to date has compared balanced solution vs. isotonic saline in this context.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

300

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Nice, France
        • Recrutement
        • CHU NICE
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Admission to emergency department or direct admission to ICU
  • Diagnosis of severe diabetic ketoacidosis requiring all the following criteria:
  • Blood or capillary glucose > 11 mmol/L
  • Ketonemia or ketonuria > 0
  • Venous or arterial pH < 7.30 or venous or arterial bicarbonate < 15 mmol/L
  • Volume of fluid administered before inclusion <1L

Exclusion Criteria:

  • Patients <18 years
  • Pregnant women
  • Patients under protection
  • Patients with a decision to withdraw life-sustaining therapy
  • Contraindication to isotonic saline or Ringer Lactate
  • Non-affiliation to social security

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Solution saline isotonique

Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:

  • During the first hour of treatment:

    • In the event of systolic arterial hypotension (SAP<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.
    • In the absence of systolic arterial hypotension (SAP>90mmHg): administration of 1L over 1 hour.
  • Between 60 minutes and 8 hours of treatment :

    • 1L over 2 hours, repeated once, then 1L over 4 hours
    • Adjust fluid resuscitation according to clinical tolerance
  • After the first 8 hours:

    • 1L over 4h then 1L over 6h
    • Clinical re-evaluation according to standard of care in participating centers
Expérimental: Sonnerie Lactate

Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:

  • During the first hour of treatment:

    • In the event of systolic arterial hypotension (SAP<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.
    • In the absence of systolic arterial hypotension (SAP>90mmHg): administration of 1L over 1 hour.
  • Between 60 minutes and 8 hours of treatment :

    • 1L over 2 hours, repeated once, then 1L over 4 hours
    • Adjust fluid resuscitation according to clinical tolerance
  • After the first 8 hours:

    • 1L over 4h then 1L over 6h
    • Clinical re-evaluation according to standard of care in participating centers

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Resolution of diabetic ketoacidosis
Délai: at 24 hours

Compare fluid resuscitaiton with Ringer Lactate to isotonic saline on the resolution of diabetic ketoacidosis at 24 hours from admission to Intensive Care Unit (ICU) in patients with severe diabetic ketoacidosis.

Resolution of ketoacidosis allowing discharge from ICU, defined as the proportion of patients with the following three criteria at 24 hours from ICU admission :

  1. capillary or blood glucose < 11 mmol/L
  2. ketonemia < 0.6 mmol/l
  3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L
at 24 hours

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Speed of resolution of metabolic disorders
Délai: at 48 hours

Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis.

Proportion of patients and number of hours ("Resolution free hours") within 48 hours of ICU admission with the following three criteria:

  1. capillary or blood glucose < 11 mmol/L
  2. ketonemia < 0.6 mmol/l
  3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L
at 48 hours
Time of resolution of metabolic disorders
Délai: at 48 hours

Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis.

Time (in hours) from ICU admission to obtain one of the following three criteria:

  1. capillary or blood glucose < 11 mmol/L
  2. ketonemia < 0.6 mmol/l
  3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L
at 48 hours
Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution
Délai: through the end of study average 24 months

Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution in patients admitted to ICU for severe diabetic ketoacidosis.

Occurrence of serious metabolic disorders during ICU stay, defined as :

  1. Kalemia < 3 mmol/L
  2. Natremia > 145 mmol/L
  3. Chloremia > 110 mmol/L
  4. Phosphoremia < 0.70 mmol/L
  5. Blood glucose < 3.8 mmol/L (i.e. 0.80 g/L)
  6. Persistent ketonemia/ketonuria 24 hours after ICU admission 2. Nature and volume (in liters) of fluid administered before inclusion and during the study period in each group 3. Protocol compliance (expressed as % of volume administered in each group)
through the end of study average 24 months
Assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications
Délai: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Occurrence of adverse events during ICU stay, defined as :

  1. Neurological disorders (Glasgow score)
  2. Acute renal failure (KDIGO classification)
  3. Cardiac disorders (supraventricular and ventricular rhythm disorders, acute coronary syndrome) 2. ICU and hospital length of stay 3. ICU mortality and Day-28 mortality
at 28 days
Assess the impact of Ringer lactate compared with isotonic saline on cardiac complications
Délai: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Occurrence of adverse events during ICU stay, defined as :

  • Cardiac disorders (supraventricular and ventricular rhythm disorders, acute coronary syndrome)
  • ICU and hospital length of stay
  • ICU mortality and Day-28 mortality
at 28 days
Assess the impact of Ringer lactate compared with isotonic saline on renal complications
Délai: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on renal, complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Measure acute renal failure with KDIGO classification.

The Kidney Disease: Improving Global Outcomes (KDIGO) classification system stratifies acute kidney injury (AKI) into levels of severity, determined by changes in serum creatinine (SCr) / estimated creatinine clearance (eCCl), as well as changes in urine output. The strata of severity of AKI can be reached by meeting the criteria for changes in SCr / eCCl or changes in urine output. There are three levels of severity, with level 1 being the least severe and level 3 the most severe.

No cut-off for the study

at 28 days
Assess the impact of Ringer lactate compared with isotonic saline on neurological complications
Délai: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on neurological complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Measure Neurological disorders with Glasgow score. The Glasgow Coma Scale (GCS) is used to objectively describe the extent of impaired consciousness in all types of patients. The scale rates patients on three aspects of reactivity: eye opening, motor responses and verbal responses. It ranges from 3 (coma) to 15 (no disturbance of consciousness). No cut-off for the study.

at 28 days

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

26 novembre 2025

Achèvement primaire (Estimé)

1 décembre 2027

Achèvement de l'étude (Estimé)

1 juillet 2028

Dates d'inscription aux études

Première soumission

8 juillet 2024

Première soumission répondant aux critères de contrôle qualité

2 août 2024

Première publication (Réel)

7 août 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 22-API-03

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .